MannKind Corp stock (US5638651064): inhaled insulin specialist draws attention after recent business updates

MannKind Corp has been back in focus after recent business updates and pipeline news in its inhaled therapeutics portfolio. Investors are watching how the diabetes and lung disease specialist executes on partnerships and revenue growth in the coming quarters.

MannKind Corp has moved back onto the radar of many biotech-focused investors following a series of recent business and pipeline updates around its inhaled insulin Afrezza and its growing portfolio in pulmonary arterial hypertension and other lung diseases, according to company communications and financial filings published in spring 2025 and early 2026. These developments have raised fresh questions about long-term revenue visibility and the role of partnerships in MannKind’s strategy for the US and global markets, as reported in corporate updates and earnings materials made available through the company’s investor relations website in that period.

In its most recent publicly available quarterly and full-year financial results, MannKind highlighted rising product sales from Afrezza and its Tyvaso DPI collaboration with United Therapeutics, alongside a still loss-making bottom line, based on filings and earnings releases posted on its investor portal in 2025. The company also discussed continued investment into its Technosphere platform and pipeline programs for rare lung diseases, according to those same documents, which outlined revenue trends, operating expenses and development priorities over the reporting period.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: MannKind Corp
• Sector/industry: Biotechnology / pharmaceuticals
• Headquarters/country: United States
• Core markets: Diabetes care and pulmonary diseases
• Key revenue drivers: Afrezza inhaled insulin, Tyvaso DPI manufacturing and royalties, Technosphere platform collaborations
• Home exchange/listing venue: Nasdaq (ticker: MNKD)
• Trading currency: USD

MannKind Corp: core business model

MannKind Corp focuses on developing and commercializing inhaled therapeutic products that use its proprietary Technosphere delivery platform, with a particular emphasis on chronic diseases that benefit from rapid drug absorption via the lungs, according to company descriptions provided on its corporate website and in investor presentations updated through 2025. Unlike many early-stage biotech firms that rely almost entirely on research milestones, MannKind combines commercial-stage products with a pipeline of new candidates, positioning itself as a hybrid between a specialty pharma business and a platform-driven biotech entity.

The company’s flagship product is Afrezza, a rapid-acting inhaled insulin for adults with diabetes that is designed to help manage blood glucose at mealtimes, as described in prescribing information and product materials accessible via the company’s digital channels and regulatory documentation in the US. MannKind markets Afrezza in the United States and works with partners in selected international territories, following a strategy that aims to leverage both direct commercialization where it has established infrastructure and licensing or distribution agreements elsewhere, as laid out in corporate updates and partnership announcements from recent years.

Beyond Afrezza, MannKind has increasingly emphasized its role as a manufacturing and development partner in inhaled therapies, most prominently through its collaboration with United Therapeutics on Tyvaso DPI, an inhaled treatment for pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease, according to joint communications and regulatory materials released after the product’s approval in the US. Under this arrangement, MannKind receives revenues related to manufacturing services and royalties, which have become a significant and growing portion of its top line, based on earnings disclosures published through its investor relations site during 2025.

The core of MannKind’s business model therefore rests on three pillars: direct sales of Afrezza in diabetes, partner-enabled products such as Tyvaso DPI in serious lung diseases, and the extension of the Technosphere platform into additional indications via internal development or collaborations. This mix offers diversified revenue streams but also exposes the company to multiple categories of risk, ranging from competitive pressure in diabetes to regulatory and reimbursement uncertainties in rare pulmonary conditions, as discussed in risk factor sections of its annual reports and filings provided to US regulators and investors in 2025.

Main revenue and product drivers for MannKind Corp

The primary revenue driver for MannKind historically has been Afrezza, which generates net revenue from prescriptions and related sales in the US diabetes market, according to the company’s quarterly and annual results released throughout 2024 and 2025. Management has repeatedly highlighted efforts to expand Afrezza usage among endocrinologists and primary care physicians, including educational initiatives and patient support programs, as noted in earnings call transcripts and presentations shared with shareholders over that period.

A key strategic development for MannKind has been the increasing contribution from Tyvaso DPI, manufactured for United Therapeutics using MannKind’s inhalation technology at its Danbury, Connecticut facility. Since launch, Tyvaso DPI-related manufacturing and royalty revenue has grown into a substantial part of the company’s total sales mix, according to financial statements and commentary accompanying results releases in 2025. This revenue stream is particularly important because it demonstrates the scalability of MannKind’s platform when paired with larger commercial partners that have established sales forces in specialty indications.

Alongside these marketed products, MannKind has been investing in pipeline programs targeting various forms of pulmonary disease and exploring opportunities in oncology and other areas where local or rapid systemic delivery via the lungs could be advantageous, based on pipeline overviews and R&D disclosures posted on its corporate and investor websites during 2025. While these programs remain at different development stages, they form an important part of the company’s long-term growth narrative and can influence investor sentiment, especially when new trial milestones or regulatory interactions are communicated to the market.

MannKind’s revenue trajectory in recent reporting periods reflects both the opportunities and challenges embedded in this portfolio. Afrezza growth has been gradual rather than explosive, constrained in part by entrenched competition from injectable insulins and newer diabetes drug classes such as GLP-1 receptor agonists, as highlighted in sector commentary and comparative analysis in business media during 2024 and 2025. At the same time, Tyvaso DPI has provided a faster-growing revenue component that is less directly exposed to primary care dynamics and more tied to specialist prescribing in rare disease, offering a measure of diversification for the company’s overall business profile.

From a financial structure perspective, MannKind’s results have shown improving revenue but continued net losses, a pattern typical for many development-focused biotech companies at this stage of maturity, according to its income statements and cash flow data included in filings and earnings reports for 2024 and 2025. The company has emphasized cost management and the efficient scaling of its manufacturing operations while also signaling that it intends to continue investing meaningfully in R&D, reflecting the balance between near-term financial discipline and long-term innovation spending that is common in the sector.

Industry trends and competitive position

MannKind operates at the intersection of the diabetes and rare lung disease markets, both of which have seen significant innovation in recent years. In diabetes, newer injectable and oral therapies have changed treatment algorithms, exerting pressure on traditional insulin franchises and creating a more complex competitive environment for alternative delivery systems like inhaled insulin, as reported in various industry reviews and healthcare analyses published in 2024 and 2025 by major medical and business outlets. This has implications for Afrezza’s uptake, as clinicians weigh convenience and rapid-acting profiles against long-term outcome data and payer coverage considerations.

In the pulmonary arterial hypertension space, therapies such as Tyvaso DPI compete within a growing but still relatively specialized market, where treatment decisions are often made by experienced specialists familiar with advanced delivery systems and complex disease management, according to sector overviews and expert commentary featured in healthcare conferences and trade publications over the past few years. The inhaled route offers certain advantages for drug delivery directly to the lungs, but it also requires careful patient training and adherence support, factors that MannKind and its partners highlight in their educational materials and professional outreach.

At a broader industry level, the use of dry-powder inhalers and advanced pulmonary delivery technologies has expanded beyond traditional asthma and COPD treatments into areas such as systemic therapies, vaccines and targeted oncology approaches, as seen in research publications and biotech pipeline surveys from 2023 to 2025. MannKind’s Technosphere platform positions the company to participate in this shift, potentially as a partner of choice for larger pharmaceutical and biotech firms seeking to develop inhaled versions of established or novel agents, according to statements from management during investor presentations and conference appearances in 2024 and 2025.

However, MannKind’s competitive position is influenced not only by its technology but also by its scale and financial resources relative to much larger industry players. The company must manage manufacturing capacity, regulatory compliance and global supply chain demands while continuing to invest in clinical development, a balancing act that can be challenging for mid-cap and smaller biotech firms. This dynamic underscores why MannKind often pursues partnership models that combine its technical know-how with the commercial infrastructure and capital of bigger companies, as reflected in its agreements with partners in pulmonary disease and other indications.

Why MannKind Corp matters for US investors

For US investors, MannKind represents a specialized exposure to inhaled therapeutics within the broader biotechnology and pharmaceutical sector, with a business model that differs from more diversified large-cap drug makers. The stock is listed on Nasdaq under the ticker MNKD, making it easily accessible to US-based retail and institutional investors through standard brokerage platforms, and it is subject to the same disclosure and governance requirements as other US-listed biotech companies, according to exchange rules and regulatory filings.

MannKind’s focus on chronic diseases that require long-term therapy, such as diabetes and pulmonary arterial hypertension, ties the company’s prospects to enduring healthcare needs in the US market. Diabetes prevalence continues to be high in the United States, and pulmonary hypertension remains a serious condition with significant unmet medical needs, factors that underpin demand for new treatment options, as highlighted in epidemiological reports and healthcare statistics regularly cited by public health authorities and medical associations. For investors constructing sector-specific portfolios, MannKind can thus offer targeted exposure to these disease areas via a differentiated drug delivery platform.

Furthermore, MannKind’s collaboration-heavy approach means that a significant part of its future performance may depend on the success of partners’ commercialization efforts and the expansion of co-developed products into new indications or geographies. This creates potential upside if partnered products outperform expectations or win additional approvals, but it also introduces dependency on counterparties’ strategic decisions and resource allocation. For US investors who are accustomed to evaluating biotech partnerships and royalty streams, MannKind’s structure may resemble other platform companies that rely on a mix of milestone payments, royalties and manufacturing income.

Because MannKind is not yet consistently profitable, US investors also tend to monitor its cash position, debt levels and access to capital markets closely. Biotech firms often fund R&D and capacity expansion through a combination of operating cash flow, equity offerings and, in some cases, debt instruments, and market sentiment can shift quickly in response to capital-raising announcements or changes in financial guidance. MannKind’s ability to balance investment in growth with maintaining a solid liquidity buffer is therefore an important consideration for those tracking the stock over multi-year horizons.

Conclusion

MannKind Corp has carved out a distinctive position in the biotech landscape by concentrating on inhaled therapies for chronic metabolic and pulmonary diseases, combining direct product sales with manufacturing and royalty income from key partnerships. While Afrezza remains central to its identity in diabetes care, the growing role of Tyvaso DPI and other Technosphere-based projects underscores the company’s evolution into a broader inhaled-therapeutics platform player. For investors, the stock offers exposure to long-duration healthcare themes and platform-based growth potential, balanced by the usual biotech risks of clinical, regulatory and commercial uncertainty, as well as the financial discipline required for a company that continues to invest heavily in research and development. How effectively MannKind executes its partnership strategy, scales its manufacturing capabilities and navigates competitive forces in both diabetes and pulmonary disease markets will likely remain core factors shaping the stock’s appeal to US and international investors in the years ahead.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.